Patients and data collection
This was a multi-center retrospective study. All patients diagnosed with NECC who were subjected to surgery at the three Gynecologic Oncology Departments, namely, the Xijing Hospital of the Fourth Military Medical University, Northwest Women’s and Children’s Hospital, and General Hospital of Western Theater Command of PLA in China between 2009 and 2022 were recruited. All clinical and pathological data were recorded, including age, FIGO stage (2018), tumor size, gestational history, history of illness, family history, treatment strategy, histological type, uterus invasion, depth of stromal invasion, lymphovascular invasion (LVSI), surgical margins, lymph node metastasis, and perineural invasive. All follow-up data were collected by telephone and from outpatient clinical records until July 28, 2022. Patients who did not undergo surgery were excluded. A total of 58 eligible patients were included. This study was approved by the Ethics Committee of the Xijing Hospital of the Fourth Military Medical University (KY20222112-C-1) and completed registration at the Chinese Clinical Trial Registry (ChiCTR2200063023).